PANEL DE DISCUSION |
In evaluating outcomes in end-stage renal disease (ESRD), as well as in other chronic diseases, QoL has become as important as morbidity and mortality. It is also a valuable parameter in the evaluation of treatment effectiveness and cost-profit analysis. QoL according to the WHO definition is not only the absence of disease, but the presence of physical, mental and social well-being.
There are different instruments to analyze the patient perception of
the physical, psychological and social domains of health. These instruments may
be non-specific or disease-specific. Non-specific instruments have been widely
used in evaluating QoL in different chronic diseases as well as in ESRD, such
as the Sickness Impact Profile (SIP) and more recently the SF-36. The Kidney
Disease Quality of Life (KDQOL) test and its short form KDQOL-SF are specific
tests developed for ESRD patients.
Several factors influence QoL in ESRD patients. After the
introduction of epoetin treatment, several studies demonstrated a significant
improvement in QoL of dialysis and pre-dialysis patients. The hemoglobin level
achieved after epoetin therapy has a close relationship to QoL scores. The
higher the hemoglobin level, the better the QoL. Other factors related to
better QoL are the socio-economic level and the level of education. However,
older age, comorbidity, diabetes and female sex are related to a worse QoL.
In pre-dialysis patients, epoetin treatment significantly improves
QoL, allowing the patient to maintain a situation of well-being until starting
dialysis. It has been shown that QoL in pre-dialysis patients deteriorates in
relation to the decrease of GFR, and a worse QoL is also related to a late
referral of the patient to the nephrologist. Older age, co-morbidity, female
sex, poor educational level and unemployment are other factors with a negative
influence in QoL. Recent studies show that QoL is a prognostic factor of
survival. ESRD patients with low QoL have a higher mortality than those
perceiving a good QoL.
Early treatment of anemia in ESRD patients is the best way to
maintain an adequate QoL in the pre-dialysis and dialysis phase, and is
associated to a good survival rate.